- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prevention of Rejection in Kidney Transplant
- Interventions
- AT-1501
- Drug
- Lead sponsor
- Eledon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Kidney Transplant Rejection
- Interventions
- AT-1501, Tacrolimus
- Drug
- Lead sponsor
- Eledon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 22 more
- Conditions
- Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
- Interventions
- Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
- Procedure · Drug
- Lead sponsor
- Tatsuo Kawai, MD, PhD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabete Type 1, Chronic Kidney Disease
- Interventions
- Tegoprubart, Islet Cell Transplant
- Drug · Biological
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 2
- States / cities
- Miami, Florida • Chicago, Illinois
- Conditions
- Kidney Transplant Rejection
- Interventions
- AT-1501, Tacrolimus
- Drug
- Lead sponsor
- Eledon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 23 more